Art

J-GLOBAL ID：201802275988409387   Reference number：18A0796087

Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study

非小細胞肺癌の治療を受けた患者におけるニボルマブの有効性と安全性: 多施設後ろ向きコホート研究【JST・京大機械翻訳】

Author (21)： Fujimoto Daichi (Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan) ,  Yoshioka Hiroshige (Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Japan) ,  Kataoka Yuki (Department of Respiratory Medicine, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan) ,  Morimoto Takeshi (Clinical Research Center, Kobe City Medical Center General Hospital, Kobe, Japan) ,  Morimoto Takeshi (Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan) ,  Kim Young Hak (Department of Respiratory Medicine, Kyoto University Hospital, Kyoto, Japan) ,  Tomii Keisuke (Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan) ,  Ishida Tadashi (Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Japan) ,  Hirabayashi Masataka (Department of Respiratory Medicine, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan) ,  Hara Satoshi (Department of Respiratory Medicine, Itami City Hospital, Itami, Japan) ,  Ishitoko Manabu (Department of Respiratory Medicine, Shiga Medical Center for Adults, Moriyama, Japan) ,  Fukuda Yasushi (Department of Respiratory Medicine, Himeji Medical Center, Himeji, Japan) ,  Hwang Moon Hee (Department of Respiratory Medicine, Osaka Red Cross Hospital, Osaka, Japan) ,  Sakai Naoki (Department of Respiratory Medicine, Otsu Red Cross Hospital, Otsu, Japan) ,  Fukui Motonari (Respiratory Disease Center, Kitano Hospital, The Tazuke-Kofukai Medical Research Institute, Osaka, Japan) ,  Nakaji Hitoshi (Department of Respiratory Medicine, Toyooka Public Hospital, Toyooka, Japan) ,  Morita Mitsunori (Department of Respiratory Medicine, Kobe City Medical Center West Hospital, Kobe, Japan) ,  Mio Tadashi (Division of Respiratory Medicine, National Hospital Organization Kyoto Medical Center, Kyoto, Japan) ,  Yasuda Takehiro (Department of Respiratory Medicine, Tenri Hospital, Nara, Japan) ,  Sugita Takakazu (Department of Respiratory Medicine, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan) ,  Hirai Toyohiro (Department of Respiratory Medicine, Kyoto University Hospital, Kyoto, Japan)
Material： Lung Cancer
Volume： 119  Page： 14-20  Publication year： 2018 
JST Material Number： W3184A  ISSN： 0169-5002  Document type： Article
Article type： 原著論文  Country of issue： Netherlands (NLD)  Language： ENGLISH (EN)

Abstract/Point： Nivolumab has been shown to be...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=18A0796087&from=J-GLOBAL&jstjournalNo=W3184A") }}

Thesaurus term： EGF receptor ,  metabasis ,  *patient ,  clinical trial ,  Pneumonia ,  retrospective cohort study ,  *non-small cell lung cancer ,  Multivariate Analysis ,  survival ratio ,  *Safety ,  *therapy ,  Mutation ,  smoking (tobacco) ,  predictive factor ,  adverse reaction
Semi thesaurus term： 有害事象 , 【Automatic Indexing@JST】

Author keywords (5)： Programmed cell death 1 ,  Programmed cell death ligand 1 ,  Pneumonitis ,  Immune-related adverse event ,  Nivolumab

JST classification (2)： Drug therapy(=pharmacotherapy)for tumors  (GE03032C) ,  Clinical application of antitumor(=antineoplastic)drugs  (GW16020L)

Terms in the title (8)： 非小細胞肺癌 ,  治療 ,  患者 ,  ニボルマブ ,  有効性 ,  安全性 ,  施設 ,  後ろ向きコホート研究